Protocol Ledger

NCT07496567 · Phase II/III · RECRUITING

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

Interventional Phase II/III clinical trial protocol NCT07496567 sponsored by EyeBiotech in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-15 Enrollment: 960 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07496567
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)960 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07496567
Protocol FieldVerified Registry Value
NCT IdentifierNCT07496567
Consolidated Lead SponsorEyeBiotech
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment960 participants (ESTIMATED)
Registered Start Date2026-04-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07496567
Hospital Research SiteLocationSite Profile
The Retina PartnersEncino, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI